medigraphic.com

2010, Number 6

<< Back Next >>

Rev Med Inst Mex Seguro Soc 2010; 48 (6)

Rapid immune response against hepatitis B using an accelerated intradermal vaccination schedule

Solórzano-Santos F, Pérez-de la Cruz L, Meléndez-Blanco SP, Álvarez-y Muñoz MT, Huerta-García GC, Miranda-Novales MG, Vázquez-Rosales G

Language: Spanish
References: 30
Page: 603-606
PDF size: 32.87 Kb.


ABSTRACT

Objective: to evaluate serum antibody levels against HBV in health care workers whom received an accelerated intradermal vaccination schedule with micro doses of recombinant vaccine.
Methods: quasi-experimental study without control group, in healthy health care workers, with no previous history of immunization against HBV. Three doses of intradermal vaccine 5 µg (0.25 mL) at time 0, 2 and 4 weeks were applied. A serum sample of 5 mL was taken at time 0, 2 and 8 weeks after the beginning of the scheme. Antibodies against HBV surface antigen (antiHB) were measured by ELISA.
Results: fifty one negative anti-HB subjects were included, 61 % female, mean of age 33 years old. After the first dose, 28 % of subjects showed seroprotection levels (a median of 312 mUI/mL). At the end of the schedule 93 % of the subjects had anti-HB antibodies, and 78 % had › 10 mUI/mL.
Conclusions: With this accelerated schedule of HBV vaccination 90 % of the subjects showed seroconversion. This scheme elicits rapid immune response and could be useful in post exposure cases


REFERENCES

  1. Lemon SM, Thomas DL. Vaccines to prevent viral hepatitis. N Engl J Med 1997;336:196-204.

  2. Centers for Disease Control and Prevention. Global progress toward universal childhood hepatitis B vaccination, 2003. MMWR 2003;52(36): 868-870. Disponible en http://www.cdc.gov/mmwr/preview/mmwrhtml/mm5236a5.htm

  3. Román S, Panduro A, Aguilar-Gutiérrez Y, Maldonado M, Vázquez-Vandyck M, Martínez-López E, et al. A low steady HBsAg seroprevalence is associated with a low incidence of HBV-related liver cirrhosis and hepatocellular carcinoma in Mexico: a systematic review. Hepatol Int 2009;3 (2):343-355.

  4. Chiquete E, Sánchez LV, Becerra G, Quintero A, Maldonado M, Panduro A. Performance of the serologic and molecular screening of blood donations for the hepatitis B and C viruses in a Mexican transfusion center. Ann Hepatol 2005; 4(4):275-278.

  5. Tanaka J. Hepatitis B epidemiology in Latin America. Vaccine 2000;18(Supl 1): S17-S19.

  6. Kershenobich D, Hurtado R, Collawn C, Bobadilla J, Cabrera G, Borovoy J, et al. Seroprevalence of viral markers of hepatitis B among health professionals. Multicenter study in Mexico. Rev Invest Clin 1990;42(4):251-256.

  7. Flores-Calderón J, Álvarez-Muñoz MT, Bustamante-Calvillo ME, Vázquez-Rosales G, Reyes-Morales H. Prevalencia de marcadores serológicos para el virus de la hepatitis B en el hospital pediátrico. Bol Med Hosp Infant Mex 1994;51(2):99-104.

  8. Roome AJ, Walsh SJ, Cartter ML , Hadler JL. Hepatitis B vaccine responsiveness in Connecticut public safety personnel. JAMA 1993;270(24):2931-2934.

  9. Navarrete-Navarro S, Álvarez-Muñoz MT, Bustamante-Calvillo ME, Vallejo- Aguilar OJ, Muñoz O, Santos-Preciado JI, Ávila-Figueroa C. Protection of health personnel against hepatitis B by DNA recombinant vaccine. Bol Med Hosp Infant Mex 1992;49(1):739-742.

  10. Playford EG, Hogan PG, Bansal AS, Harrison K, Drummond D, Looke DF, et al. Intradermal recombinant hepatitis B vaccine for healthcare workers who fail to respond to intramuscular vaccine. Infect Control Hosp Epidemiol 2002;23(2):87- 90.

  11. Margolis HS, Presson AC. Host factors related to poor immunogenicity of hepatitis B vaccine in adults. JAMA 1993;270(24):2971-2972.

  12. Connor BA, Blatter MM, Beran J, Zou B, Trofa AF. Rapid and sustained immune response against hepatitis A and B achieved with combined vaccine using an accelerated administration schedule. J Travel Med 2007;14:9-15.

  13. Saltoglu N, Inal AS, Tasova Y, Kandemir O. Comparison of the accelerated and classic vaccination schedules against hepatitis B: three-week hepatitis B vaccination schedule provides immediate and protective immunity. Ann Clin Microbiol Antimicrob 2003;2:10. Disponible en http://www.ncbi.nlm.nih. gov/pmc/articles/PMC293476/

  14. Wahl M, Hermodsson S, Iwarson S. Hepatitis B vaccination with short dose intervals. A possible alternative for post-exposure prophylaxis? Infection 1988; 16(4):229-232.

  15. Leonardi S, Barone P, Musumeci S. Intradermal hepatitis B vaccination: fiveyear follow-up. Pediatr Infect Dis J 1995;14(8):716-717.

  16. Vázquez G, Mendoza-Guevara L, Álvarez T, Aguilar A, Morales A, Rodríguez F, et al. Comparison of the response to the recombinant vaccine against hepatitis B virus in dialyzed and nondialyzed children with CRF using different doses and routes of administration. Adv Perit Dial 1997;13:291-296.

  17. Miller KD, Gibbs RD, Mulligan MM, Nutman TB, Francis DP. Intradermal hepatitis B virus vaccine: immunogenicity and side-effects in adults. Lancet 1983;2(8365-8366):1454-1456.

  18. Zuckerman AJ. Appraisal of intradermal immunization against hepatitis B. Lancet 1987;1(8530): 435-436.

  19. Halsey NA, Reppert EJ, Margolis HS, Francis DP, Fields HA. Intradermal hepatitis B vaccination in an abbreviated schedule. Vaccine 1986;4(4):228- 232.

  20. Henderson EA, Louie TJ, Ramotar K, Ledgerwood D, Hope KM, Kennedy A. Comparison of higherdose intradermal hepatitis B vaccination to standard intramuscular vaccination of healthcare workers. Infect Control Hosp Epidemiol 2000;21 (4):264-269.

  21. McMaster KR, Roper JK, Carter JB. Intradermal hepatitis B vaccination in a 300-bed primary care hospital: experience with a recombinant vaccine in a four-dose schedule. Am J Infect Control 1993; 21(6):283-288.

  22. Yamashiki M, Kosaka Y, Nishimura A. An effective intradermal hepatitis B vaccination. Vaccine 1997;15(15):1618-1623.

  23. Kyi KP, Oo KM, Htun MM, Tun WM, Aye KK, Oo SS, et al. Clinical trial of the intradermal administration of hepatitis B vaccine produced at the Department of Medical Research, Myanmar. Vaccine 2002;20(11-12):1649-1652.

  24. Kurugöl Z, Erensoy S, Aksit S, Egemen A, Bilgic A. Low-dose intradermal administration of recombinant hepatitis B vaccine in children: 5-year followup study. Vaccine 2001;19(28-29):3936-3939.

  25. Wiström J, Settergren B, Gustafsson A, Juto P, Norrby RS. Intradermal vs. intramuscular hepatitis B vaccinations. JAMA 1990;264(2):181-182.

  26. Ghabouli MJ, Sbouri AH, Shoeibi N, Bajestan SN, Baradaran H. High seroprotection rate induced by intradermal administration of a recombinant hepatitis B vaccine in young healthy adults: comparison with standard intramuscular vaccination. Eur J Epidemiol 2004;19(9):871-875.

  27. Osorio JE, Zuleger CL, Burger M, Chu Q, Payne LG, Chen D. Immune responses to hepatitis B surface antigen following epidermal powder immunization. Immunol Cell Biol 2003;81(1):52-58.

  28. Chau KF, Cheng YL, Tsang DN, Choi KS, Wong KM, Chak WL, et al. Efficacy and side effects of intradermal hepatitis B vaccination in CAPD patients: a comparison with the intramuscular vaccination. Am J Kidney Dis 2004;43(5):910-917.

  29. Elisbão Mdo C, Baldy JL, Bonametti AM, Reiche EM, Morimoto HK, Pontello R, et al. Intradermal vaccination of adults with three low doses (2 micrograms) of recombinant hepatitis B vaccine. II. Persistence of immunity and induction of immunologic memory. Mem Inst Oswaldo Cruz 2003;98(8):1109-1113.

  30. Baldy JL, Elisbao Mdo C, Anzai ET, Pontello R, Reiche EM, Zaha-Inouye MM, et al. Intradermal vaccination of adults with three low doses (2 micrograms) of recombinant hepatitis B vaccine. I. Seroconversion rate and adverse effects. Mem Inst Oswaldo Cruz 2003;98(8):1101-1107.




2020     |     www.medigraphic.com